Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update

Slide: 11 of 40

Clinical Questions Addressed by the CER (1 of 5)

Key Question (KQ) 1 asked: What are the comparative benefits in fracture reduction among the following therapeutic modalities for LBD?

  • Bisphosphonate medications, specifically: alendronate (Fosamax®, oral); risedronate (Actonel®; oral once-a-week); ibandronate (Boniva®); and zoledronic acid (Reclast®, Zometa®, oral and intravenous)
  • Denosumab (Prolia®)
  • Menopausal Estrogen therapy for women (numerous brands and routes of administration)
  • Parathyroid hormone (PTH): 1–34 PTH (teriparatide; Forteo®)
  • Selective estrogen receptor modulators (SERMs), specifically: Raloxifene (Evista®)
  • Calcium
  • Vitamin D
  • Combinations or sequential use of above
  • Exercise in comparison to the agents above